Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

The 2022 Tandem Meetings | Procalcitonin as a biomarker to distinguish between CRS & infections after CAR-T therapy

Radhika Bansal, MBBS, Mayo Clinic, Rochester, MN, gives an overview of the results of a study evaluating the use of procalcitonin as a biomarker to distinguish between cytokine release syndrome (CRS) and infections, two of the most common complications observed after treatment with CAR-T therapy. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.